Genetic Markers And Treatment Of Male Obesity

Abstract

Some aspects of this disclosure provide methods for treating obesity in subjects carrying a variant allele of the carboxypeptidase D (CPD) gene with perindopril, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof; a compound of Formula II, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof; or a compound of Formulae III-V, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof. Some aspects of this disclosure also provide methods for identifying a subject predisposed to obesity and/or sensitive to treatment with perindopril; a compound of Formula II, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof; or a compound of Formulae III- V, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof based on the subject carrying a variant allele of the CPD gene. Pharmaceutical compositions for treating obesity and kits for detecting a variant allele of the CPD gene and/or for identifying a subject who is predisposed to obesity or who would benefit from treatment with perindopril; a compound of Formula II, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof; or a compound of Formulae III- V, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof are also provided.


Claims

Download Citation


Sign in to the Lens

Feedback